1. Mechanisms of degeneration in Parkinson's disease / B. Wolozin. [et al.] -- 2. Underlying biochemical and molecular mechanisms of dyskinesia / H. Reichmann, P. Riederer -- 3. Molecular neuropathology of parkinsonism / D.W. Dickson -- 4. Familial parkinsonian mutations affect the ability of catecholaminergic neurons to withstand proteasome inhibition / M.R. Cookson -- 5. Acetylcholinesterase, cholinergic signaling and Parkinson's disease / Y. Ben-Shaul, H. Bergman, H. Soreq -- 6. Bone marrow stem cells : possible source for cell therapy in Parkinson's disease / Y.S. Levy. [et al.] -- 7. Insulin-like growth factor I and intracellular signal transduction pathways in aging and dementia / W.-H. Zheng, R. Quirion -- 8. The interrelationships between gait and cognitive function / N. Giladi, P.L. Sheridan, J.M. Hausdorff -- 9. Advances in gene transfer and pharmacological regulation of protein aggregation in the treatment of Alzheimer's and Parkinson's diseases / P. Bar-On. [et al.] -- 10. [Science symbol] and [beta]-Synucleins : two parent proteins that display similar anti-apoptotic phenotypes but distinct responses to 6-hydroxydopamine-induced toxicity / F. Checler, C. Alves da Costa -- 11. Functional genomics and pharmacogenetics in Alzheimer's disease / R. Cacabelos. [et al.] -- 12. The genetics of tau and neurodegenerative disease / B. Kraemer, I. D'Souza, G.D. Schellenberg -- 13. Amyloid plaques and neurofibrillary tangles in a triple transgenic model : qualitative similarities with human Alzheimer's neuropathology / S. Oddo, F.M. LaFerla -- 14. Apolipoprotein E and Alzheimer's disease : what has a decade told us? / K.A. Crutcher -- 15. Comparison of the effects of apolipoprotein E4 on presynaptic and cytoskeletal plasticity following environmental stimulation / O. Levi, D.M. Michaelson -- 16. Cholesterol and the A[beta] cascade : pathological implication of apolipoprotein E in Alzheimer's disease / K. Yanagisawa -- 17. Brain inflammation and psychogeriatric disease / H. Akiyama, H. Uchikado -- 18. Neuroinflammatory mechanisms are involved in the early steps of the pathological cascade in Alzheimer's disease / P. Eikelenboom. [et al.] -- 19. Vascular nitric oxide : a key molecule in Alzheimer's disease pathogenesis / J.C. de la Torre -- 20. Alzheimer pathology and endoplasmic reticulum stress / T. Kudo -- 21. Molecular mechanism of amyloid [beta]-peptide-induced impairment of neurotransmission and memory in relation to oxidative stress / K. Yamada, H.-C. Kim, T. Nabeshima --

22. Regulating factors for microglial activation : implication for Alzheimer's disease and brain damage / V.R.M. Lombardi -- 23. Cerebrospinal fluid phosphorylated tau protein at serine 199 is a useful diagnostic biomarker in Alzheimer's disease and mild cognitive impairment / K. Urakami -- 24. Stem cell strategies for Alzheimer's disease / K. Sugaya -- 25. Can mild cognitive impairment predict Alzheimer's disease? / H. Soininen -- 26. Water quality and cholesterol-induced pathology : differential effects of the M-1 muscarinic receptor agonist AF267B on accumulation of Alzheimer-like amyloid [beta] in rabbit brain / D.L. Sparks. [et al.] -- 27. Lack of effect of certoparin in P301L mutant tau pathology / M. Walzer. [et al.] -- 28. Heparin-derived oligosaccharides as potential therapeutic agents in senile dementia and stroke / Q. Ma. [et al.] -- 29. Glycosaminoglycans and neuroprotection : effect on cholinergic neurodegeneration / B. Dudas -- 30. Orchestration of the functional subsites in the acetylcholinesterase active center : contribution to catalytic perfection and high reactivity toward specific ligands / A. Shafferman -- 31. Altered glycosylation of acetylcholinesterase in the Alzheimer's disease brain : involvement of [science symbol]7 nicotinic acetylcholine receptors / D.H. Small, L.R. Fodero, J. Saez-Valero -- 32. Cholinotrophic alterations in individuals with mild cognitive impairment and Alzheimer's disease / E.J. Mufson. [et al.] -- 33. Pharmacological properties of TV3326, a cholinesterase and brain selective monoamine oxidase inhibitor for the treatment of dementia co-morbid with depression / M. Weinstock, M.B.H. Youdim -- 34. Physostigmine and its analog phenserine have different effects on Alzheimer amyloid-[beta] precursor protein / D.K. Lahiri. [et al.] -- 35. Translation and processing of amyloid precursor protein (APP) by an M1 muscarinic agonist and an acetylcholinesterase inhibitor : the role of APP mRNA 5'-untranslated region sequences / J.T. Rogers. [et al.] -- 36. Modulation of Alzheimer's amyloidosis by statins : possible mechanisms of action / S. Petanceska, M. Pappolla, L.M. Refolo -- 37. [Beta]-secretase : progress and questions / M. Citron -- 38. Tau phosphorylation and assembly in tauopathies / J. Avila. [et al.] -- 39. Alzheimer's disease : a true tauopathy fueled by amyloid precursor protein dysfunction / A. Delacourte -- 40. Neurofibrillary degeneration : a promising target for the treatment of Alzheimer's disease and other tauopathies / K. Iqbal. [et al.] -- 41. Neuropathology and tau / K.A. Jellinger. [et al.] -- 42. Conformational analysis of tau and tau aggregates by fluorescence spectroscopy / M. von Bergen. [et al.] -- 43. Transglutaminase-catalyzed cross-linking of tau in Alzheimer's disease and progressive supranuclear palsy / N.A. Muma, R.A. Halverson -- 44. The impact of extracellular amyloid-[beta] (A[beta]) peptides on cortical neurotransmitters and of intracellular A[beta] accumulation on protein expression / A.C. Cuello. [et al.] -- 45. Activation of Wnt signaling protects from amyloid-[beta]-peptide neurotoxicity / N.C. Inestrosa. [et al.] -- 46. Human prion diseases / T. Pan. [et al.].